Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
NCT02135874
Completed
This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly diagnosed or has returned after a period of improvement (relapsed). Drugs used in chemotherapy, such as clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia
Register for Updates
Effectiveness of Cervical Transforaminal Epidural Steroid Injection
NCT04544683
Completed
Study Purpose: This study is intended to monitor outcomes for 1 year following cervical TFESI. Based on current clinic volume and enrollment rates into a current study of cervical epidural injections that is nearing completion, we conservatively estimate a study enrollment period of 18 months and a total period of 2.5 years from enrollment to final follow-up data collection. If the study were to theoretically start enrolling in July 2019, we would anticipate completion by February 2022. Object... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/16/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Cervical Radiculopathy, Cervical Spondylosis, Disk, Herniated
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +35 locations
Conditions: COVID-19
Register for Updates
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT02119468
Completed
This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple myeloma. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify and regulate the immune system and may stop cancer cells from growing. Giving ixazomib with pomalidomide... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Mayo Clinic, Scottsdale, Arizona +4 locations
Conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Register for Updates
Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye
NCT04498468
Terminated
To determine efficacy and safety profile of dexamethasone 0.4mg lacrimal insert in dry eye related ocular surface inflammation.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/13/2024
Locations: Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Dry Eye
Register for Updates
Liposomal Bupivacaine in Shoulder Arthroscopy
NCT04461028
Withdrawn
Background: The research study is being conducted to see if using the liposomal Bupivacaine for the Interscalene block will improve the patient pain control and the whole patient's experience 48 hours after surgery when compared to using the regular Marcaine (bupivacaine hydrochloride) in addition to the dexamethasone. All preoperative, surgical, post-operative care in the recovery room, and discharge instructions will be the same as any other patient undergoing this surgery. Study procedures... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Rotator Cuff Tears
Register for Updates
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
NCT00381680
Completed
This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giv... Read More
Gender:
ALL
Ages:
Between 1 year and 29 years
Trial Updated:
03/04/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +172 locations
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
Register for Updates
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
NCT04514029
Active Not Recruiting
Open-label, single-arm, single center pilot study to assess safety and feasibility of administering dexamethasone intrathecally and simvastatin orally during axicabtagene ciloleucel (axi-cel) treatment. Feasibility will be measured by the proportion of patients completing two-thirds (2/3) of their assigned treatments. The study will be deemed feasible if 2/3 or more of the patients complete 2/3 or more of their allocated treatments.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/23/2024
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Lymphoma
Register for Updates
Dexamethasone for Migraine - Dose Comparison
NCT04112823
Completed
Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized comparison of two different doses of dexamethasone for acute migraine. All patients will also be treated with metoclopramide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Migraine
Register for Updates
Ideal Steroids for Asthma Treatment in the PICU
NCT03900624
Completed
Determine if differences in (1) pediatric intensive care unit length of stay, (2) continuous nebulized albuterol duration, and (3) a composite outcome of advanced asthma therapy incidence including use of non-invasive ventilation (NIV), terbutaline, inhaled helium and mechanical ventilation between cohorts of children admitted with status asthmaticus to the PICU treated with either IV dexamethasone (DM) or methylprednisolone (MP).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
02/19/2024
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Conditions: Asthma Childhood
Register for Updates
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
NCT04329728
Recruiting
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Gender:
ALL
Ages:
Between 12 years and 95 years
Trial Updated:
02/13/2024
Locations: City of Hope, Duarte, California +10 locations
Conditions: Lymphoid Malignancies
Register for Updates
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
NCT03435003
Completed
Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and aims to assess the effect of a post-operative nausea and vomiting-specific intervention. The investigators hypothesize that the intervention group will experience a reduction of nausea-related prolonged hospital stay and s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Register for Updates